V. Samnotra

Remission of paroxysmal atrial fibrillation with iron reduction in haemophilia A

P. Steiner, L. Zacharski, D. Ornstein, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC)

W. Oh, A. Fojo, M. Ernstoff, 2007 .

An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial

Ping Wang, E. Ratner, G. Konecny, 2021, Gynecologic Oncology.

Effect of Pevonedistat, an Investigational NEDD8‐Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors

K. Venkatakrishnan, D. Faller, D. Mould, 2022, Clinical pharmacology in drug development.

MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC).

B. Monk, S. Waggoner, R. Coleman, 2022, Journal of Clinical Oncology.

Model‐Based Meta‐Analysis for Multiple Myeloma: A Quantitative Drug‐Independent Framework for Efficient Decisions in Oncology Drug Development

K. Venkatakrishnan, Z. Hua, N. Gupta, 2017, Clinical and translational science.

Primary adrenocortical tumors: EGFR, c-Kit and Her-2/neu receptor staining patterns

M. Korc, M. Ernstoff, J. Heaney, 2005 .

Remission of paroxysmal atrial fibrillation with iron reduction in haemophilia A

V. Samnotra, A. Bhargava, C. Rauwerdink, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).

Aarti Tarkar, N. Cloven, V. Samnotra, 2023, Gynecologic oncology.